Cover Image
市場調查報告書

人類巨細胞病毒包膜糖蛋白B (gB):開發中產品分析

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 371948
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
人類巨細胞病毒包膜糖蛋白B (gB):開發中產品分析 Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018
出版日期: 2018年05月22日 內容資訊: 英文 48 Pages
簡介

本報告提供以人類巨細胞病毒包膜糖蛋白B (gB)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

人類巨細胞病毒包膜糖蛋白B (gB) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Astellas Pharma Inc.
  • Trellis Bioscience, Inc.
  • Vakzine Projekt Management GmbH
  • VBI Vaccine Inc
  • Vical Incorporated

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1476TDB

Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
  • Merck & Co Inc
  • Novartis AG
  • Trellis Bioscience Inc
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc
  • Vical Inc
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
  • Bispecific Monoclonal Antibody to Target CD3 and gB for Cytomegalovirus (HHV-5) Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSJ-148 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CyMVectin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cytomegalovirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PPCM - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRL-345 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBI-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBI-1901 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VPM-2001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
  • Featured News & Press Releases
  • May 10, 2018: VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
  • Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
  • Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
  • Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
  • Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelona
  • Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
  • Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
  • Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine
  • May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
  • Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
  • Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
  • Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
  • Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
  • Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate
  • Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Merck & Co Inc, H1 2018
  • Pipeline by Novartis AG, H1 2018
  • Pipeline by Trellis Bioscience Inc, H1 2018
  • Pipeline by Vakzine Projekt Management GmbH, H1 2018
  • Pipeline by VBI Vaccines Inc, H1 2018
  • Pipeline by Vical Inc, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top